Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Patients Rank Pharma Companies in New Perspective Survey

According to PatientView’s newly released “Corporate Reputation of Pharma – From the Patient Perspective,” the majority of people tend to hold a negative or indifferent view of the pharmaceutical industry’s reputation.

Read More »

Life Sciences Industry Threatened by Skills Shortage

There is something of a recurring theme among the life science, healthcare and biopharma industries: a shortage of skilled employees will lead to a decrease in innovation.

Read More »

Nocion Therapeutics Launches With $27 Million to Focus on Chronic Cough and Pain

Nocion Therapeutics launched in Cambridge, Mass., with a $27 million series A raise this week.

Read More »

White House Continues to Tackle Opioid Abuse With $350 Million R&D Initiative

The White House is expanding its war on opioid addiction with a $350 million addiction research and treatment initiative.

Read More »

Talaris Rebrands With New Leadership Team

Privately held Talaris Therapeutics secured $100 million in a Series A financing round as the company undergoes a rebranding with a new leadership team.

Read More »

Arrakis to Create New Class of rSM Oncology Drugs

With a $75 million infusion of new financing, Massachusetts-based Arrakis Therapeutics will focus the company’s pipeline on oncology and genetically validated targets in other diseases.

Read More »

Acting Commissioner Ned Sharpless Affirms Commitment to FDA’s Current Course

U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.

Read More »

Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Cornerstone

Six months after forging a hepatitis B drug development deal valued at more than $3.7 billion with Arrowhead Pharmaceuticals, Janssen Pharmaceutical presented data that showed the RNA interference (RNAi) therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.

Read More »

PureTech Health Inks Deal with Boehringer Ingelheim for Immuno-Oncology

PureTech Health signed a research collaboration deal with Germany’s Boehringer Ingelheim to develop novel product candidates using the Boston-based and London-listed company’s proprietary lymphatic targeting technology for immune modulation.

Read More »

Axsome’s AXS-05 Helps Patients Quit Smoking Significantly in Phase II Trial

Axsome Therapeutics announced that the New York City-based company’s AXS-05 met the primary endpoint for smoking cessation treatment.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom